Shinya Yamamoto1,2, Takashi Chishima3, Yukako Shibata1, Shiori Inoue1, Fumi Harada1, Hideki Takeuchi1, Akimitsu Yamada4, Kazutaka Narui2, Itaru Endo4. 1. Department of Breast Surgery, Yokohama Rosai Hospital, Yokohama, Japan. 2. Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Japan. 3. Department of Breast Surgery, Yokohama Rosai Hospital, Yokohama, Japan; chishima-t@yokohamah.johas.go.jp. 4. Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Abstract
BACKGROUND/AIM: There are few models predicting breast cancer prognosis among patients receiving neoadjuvant chemotherapy (NAC) for estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative (luminal) breast cancer. We examined whether biological features (BFs) of residual tumors are prognostic factors following NAC. PATIENTS AND METHODS: We enrolled patients with remnant tumors following NAC for luminal breast cancer and evaluated clinical stage, pathological stage, BFs prior to NAC, and BFs following NAC as prognostic factors. BFs were divided into high and low risk using the previously reported YR-IHC4 model calculated according to ER, progesterone receptor (PgR), HER2, and the proliferation marker Ki-67. RESULTS: A total of 57 patients were enrolled in the current study. We observed a statistically significant difference in relapse-free survival (RFS) between the BF risk categories via YR-IHC4 predictions following NAC (p=0.044). The 5-year RFS rates of the BF low- and high-risk groups following NAC were 84.2% and 52.5%, respectively. CONCLUSION: BFs of residual tumors following NAC may be important prognostic factors in luminal breast cancer. Copyright
BACKGROUND/AIM: There are few models predicting breast cancer prognosis among patients receiving neoadjuvant chemotherapy (NAC) for estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative (luminal) breast cancer. We examined whether biological features (BFs) of residual tumors are prognostic factors following NAC. PATIENTS AND METHODS: We enrolled patients with remnant tumors following NAC for luminal breast cancer and evaluated clinical stage, pathological stage, BFs prior to NAC, and BFs following NAC as prognostic factors. BFs were divided into high and low risk using the previously reported YR-IHC4 model calculated according to ER, progesterone receptor (PgR), HER2, and the proliferation marker Ki-67. RESULTS: A total of 57 patients were enrolled in the current study. We observed a statistically significant difference in relapse-free survival (RFS) between the BF risk categories via YR-IHC4 predictions following NAC (p=0.044). The 5-year RFS rates of the BF low- and high-risk groups following NAC were 84.2% and 52.5%, respectively. CONCLUSION: BFs of residual tumors following NAC may be important prognostic factors in luminal breast cancer. Copyright
Authors: Soonmyung Paik; Gong Tang; Steven Shak; Chungyeul Kim; Joffre Baker; Wanseop Kim; Maureen Cronin; Frederick L Baehner; Drew Watson; John Bryant; Joseph P Costantino; Charles E Geyer; D Lawrence Wickerham; Norman Wolmark Journal: J Clin Oncol Date: 2006-05-23 Impact factor: 44.544
Authors: Elizabeth A Mittendorf; Jacqueline S Jeruss; Susan L Tucker; Aparna Kolli; Lisa A Newman; Ana M Gonzalez-Angulo; Thomas A Buchholz; Aysegul A Sahin; Janice N Cormier; Aman U Buzdar; Gabriel N Hortobagyi; Kelly K Hunt Journal: J Clin Oncol Date: 2011-04-11 Impact factor: 44.544
Authors: Katie M O'Brien; Stephen R Cole; Chiu-Kit Tse; Charles M Perou; Lisa A Carey; William D Foulkes; Lynn G Dressler; Joseph Geradts; Robert C Millikan Journal: Clin Cancer Res Date: 2010-12-15 Impact factor: 12.531
Authors: Melissa A Troester; Xuezheng Sun; Emma H Allott; Joseph Geradts; Stephanie M Cohen; Chiu-Kit Tse; Erin L Kirk; Leigh B Thorne; Michelle Mathews; Yan Li; Zhiyuan Hu; Whitney R Robinson; Katherine A Hoadley; Olufunmilayo I Olopade; Katherine E Reeder-Hayes; H Shelton Earp; Andrew F Olshan; Lisa A Carey; Charles M Perou Journal: J Natl Cancer Inst Date: 2018-02-01 Impact factor: 13.506
Authors: M Colleoni; V Bagnardi; N Rotmensz; S Dellapasqua; G Viale; G Pruneri; P Veronesi; R Torrisi; A Luini; M Intra; V Galimberti; E Montagna; A Goldhirsch Journal: Ann Oncol Date: 2009-02-13 Impact factor: 32.976
Authors: Molly E Klein; David J Dabbs; Yongli Shuai; Adam M Brufsky; Rachel Jankowitz; Shannon L Puhalla; Rohit Bhargava Journal: Mod Pathol Date: 2013-03-15 Impact factor: 7.842
Authors: Stephen R D Johnston; Nadia Harbeck; Roberto Hegg; Masakazu Toi; Miguel Martin; Zhi Min Shao; Qing Yuan Zhang; Jorge Luis Martinez Rodriguez; Mario Campone; Erika Hamilton; Joohyuk Sohn; Valentina Guarneri; Morihito Okada; Frances Boyle; Patrick Neven; Javier Cortés; Jens Huober; Andrew Wardley; Sara M Tolaney; Irfan Cicin; Ian C Smith; Martin Frenzel; Desirée Headley; Ran Wei; Belen San Antonio; Maarten Hulstijn; Joanne Cox; Joyce O'Shaughnessy; Priya Rastogi Journal: J Clin Oncol Date: 2020-09-20 Impact factor: 50.717